Drug Policy Watch · State Brief 2026

Massachusetts

Snapshot (structured)

Adult-use cannabis: Legal, voter-approved 2016, retail sales since 2018; possession and purchase limit doubled to 2 ounces effective April 2026.
Medical cannabis: Legal since 2012 (voter-approved 2012, sales from 2015); vertical integration requirement for medical operators repealed in 2026.
Home grow: Legal, up to 6 plants per adult, max 12 per household.
Intoxicating hemp / hemp THC: Heavily restricted; THC and CBD food and beverages banned by DPH/ABCC guidance; state hemp program decimated; the Cannabis Control Commission was directed in 2026 to study intoxicating hemp regulation.
Psychedelics: Illegal; 2024 ballot legalization (Question 4) failed 57-43; therapeutic-access and pilot-program bills active in 2025-2026 but not enacted.
Broad decriminalization: Cannabis only; no Oregon/Measure 110-style broad drug decriminalization.
Harm reduction: Strong (statewide naloxone standing order, legal syringe services, fentanyl test strips legalized 2024); overdose prevention centers proposed repeatedly but not authorized.
Governor (party): Maura Healey (Democrat).
Legislature control: Democratic supermajority in both chambers (Senate roughly 35-5, House roughly 134-25 plus one independent; figures per Ballotpedia).
Citizen ballot initiatives allowed: Yes (indirect initiative process).
Enclosure pressure score: 3/5

Cannabis

Massachusetts legalized adult-use cannabis by ballot (2016 Question 4), with licensed adult-use retail beginning in November 2018. Medical cannabis has been legal since the 2012 ballot measure, with dispensary sales from 2015. Adults 21 and older may possess and, as of April 2026, purchase up to 2 ounces of flower (or equivalent), doubled from 1 ounce. Home cultivation is permitted: up to 6 plants per adult and 12 per household.

The defining 2026 action is H.5350, An Act Modernizing the Commonwealth's Cannabis Laws, signed by Governor Maura Healey on April 19, 2026. It is the conference compromise between the House bill H.4206 and the Senate bill S.2749. Key provisions reported by Vicente LLP, Foley Hoag, and the Cannabis Business Times: - Doubles the possession and purchase limit to 2 ounces (effective April 19, 2026 via a Commission administrative order). - Lifts retail license caps and raises the cap on licenses a single entity may hold from 3 to 6. - Ends the vertical integration requirement for medical marijuana licensees, letting medical operators specialize in cultivation, manufacturing, or retail. - Expands adult-use delivery potential statewide. - Restructures the Cannabis Control Commission from 5 commissioners to 3, all appointed by the Governor (removing the shared appointment authority previously held by the Treasurer and Attorney General). - Directs the Commission to study and recommend regulation of intoxicating hemp.

Market structure: Massachusetts is a competitive, non-residency, license-capped-but-loosening market with significant MSO presence alongside independents and social-equity operators. Adult-use sales reached about $1.65 billion in calendar 2025 per the Commission. Taxes on adult use are 6.25% state sales tax, 10.75% state excise, and an optional local tax up to 3%, for a maximum of about 20%; medical cannabis is untaxed.

Other 2026 developments: the Commission unanimously approved final social consumption (on-site use) regulations in December 2025, anticipated to take effect January 2, 2026, with the first social consumption permits reserved for social equity and economic empowerment applicants.

Hemp

Massachusetts treats intoxicating and ingestible hemp-derived cannabinoids very restrictively. The Department of Public Health, with the Alcoholic Beverages Control Commission, has issued guidance prohibiting the sale of food and beverages containing hemp-derived CBD and/or THC, and it is unlawful to sell alcoholic beverages containing THC or CBD. The result is what the Boston Globe (April 2026) described as a decimated program: licensed hemp growers/processors fell from a 2019 peak of about 122 to roughly 17 companies by March 2026, an approximately 86% decline. Hemp cultivation and processing licensing is handled by the Massachusetts Department of Agricultural Resources (MDAR) under M.G.L. c.128 sections 116-123 and 330 CMR 32.00; 2026 producer/processor license and renewal forms are active.

Federal exposure: the federal hemp definition change (the closed-the-loophole provision attached to a government funding/reopening deal signed by President Trump) gives hemp-derived cannabinoid businesses until roughly November 12, 2026 to come into compliance before the new federal limits on intoxicating hemp take effect. Because Massachusetts already bans most intoxicating hemp products, the practical in-state disruption may be smaller than in permissive states, but the federal change reinforces the existing prohibition. The 2026 cannabis law (H.5350) directs the Cannabis Control Commission to study and recommend a regulatory framework for intoxicating hemp, which is the main pending state action. Exact future state rules are unconfirmed pending that study.

Psychedelics

Psychedelics remain illegal in Massachusetts. In November 2024, voters rejected Question 4 (the Natural Psychedelic Substances Initiative) by roughly 57-43, which would have decriminalized possession and home cultivation of five natural psychedelics for adults 21+ and created supervised therapeutic-access centers. Under the state constitution, no substantially similar initiative petition could be refiled for two years, which would clear the path for the 2026 cycle.

Legislative activity in the 2025-2026 session (194th General Court) has been substantial even after the ballot loss: - About 10 psychedelics-related bills were filed at the start of 2025. - S.1400 (a broad psychedelic-assisted therapy pilot using the term "psychedelics") advanced out of the Joint Committee on Public Health on a unanimous vote in mid-September 2025; it leaves most design to the Department of Public Health. - H.2203 would create a broader psilocybin access program; H.4200 proposes a narrower pilot incorporating compounds such as MDMA or ibogaine in licensed treatment facilities. - H.4050 (introduced April 22, 2025) addresses adult use, support services, cultivation, and taxation of psilocybin-containing fungi. Sponsor and chamber details for individual bills beyond what is listed are unconfirmed; see the live tracker links in Sources. As of mid-2026, no psychedelic bill has been enacted and psilocybin remains Schedule I in Massachusetts. Note: a Marijuana Moment headline framed committee action as lawmakers voting to "legalize psilocybin and establish a framework for therapeutic access," but this refers to committee advancement of pilot/therapy legislation, not enactment; treat as advanced-not-enacted.

Broader drug policy

Decriminalization: Massachusetts decriminalized small-amount cannabis possession by ballot in 2008 and legalized adult use in 2016, but has not adopted broad decriminalization of other controlled substances. Possession of other drugs remains criminal.

Harm reduction: Among the strongest in the nation. - Naloxone: statewide standing order allows pharmacists to dispense naloxone rescue kits to at-risk persons and bystanders. - Syringe services: numerous legal syringe service/exchange programs operate, with mobile and pharmacy access. - Drug checking / fentanyl test strips: a 2024 law established criminal and civil liability protections for good-faith provision or use of fentanyl test strips and drug-checking equipment; DPH distributed nearly 400,000 fentanyl test strips in 2024. Fentanyl was present in 88.6% of opioid-related overdose deaths in 2024. - Overdose prevention centers (supervised consumption): repeatedly proposed (refiled bills associated with Rep. Marjorie Decker, Rep. John Lawn, and Sen. Julian Cyr, cited in 2025 reporting as H.2196 / S.1393; bill numbers unconfirmed against the official site), but not authorized; OPC provisions were stripped from a 2025 bill (reported as H.5143) in negotiations. A July 2025 federal executive order directed SAMHSA grants away from supervised-consumption programs, adding pressure.

Sentencing and expungement: A 2022 cannabis law update expedited expungement of now-decriminalized prior offenses and created the Social Equity Trust Fund. Governor Healey pardoned misdemeanor marijuana possession convictions predating March 13, 2024. Additional expungement bills (including a state-initiated process) have been proposed in 2025-2026; specifics unconfirmed.

Overdose and treatment policy: The state runs a robust Bureau of Substance Addiction Services within DPH; 2025 reporting noted reductions in fatal opioid overdoses. Treatment access and medication-assisted treatment are state priorities.

Political landscape

Governor: Maura Healey (Democrat), pro-reform on cannabis modernization; signed H.5350 and pardoned past misdemeanor marijuana convictions.

Legislature: Democratic trifecta with veto-proof supermajorities in both chambers. Per Ballotpedia, the Senate is roughly 35 Democrats to 5 Republicans and the House roughly 134 Democrats to 25 Republicans plus one independent. Exact current seat counts can shift with vacancies; treat as approximate.

Key committees: Joint Committee on Cannabis Policy (cannabis bills); Joint Committee on Public Health (psychedelics, harm reduction). Rep. Daniel Donahue of Worcester chaired the cannabis conference committee on the House side and is a named driver of the 2026 modernization law, framing it as restructuring the CCC and supporting social equity businesses.

Named reform champions (with focus): - Rep. Daniel Donahue (cannabis modernization, CCC restructure, equity). - Sen. Julian Cyr, Rep. Marjorie Decker, Rep. John Lawn (overdose prevention centers / harm reduction). - Sen. Cindy Creem (fentanyl test strip / drug-checking protections). Equity advocacy organizations include Equitable Opportunities Now (EON) and the Marijuana Policy Project.

Named opponents: No single high-profile legislative champion of prohibition is confirmed in 2026 sources. The Massachusetts Municipal Association raised concerns to the conference committee about overregulation, and host-community/municipal interests are the main institutional friction. Question 4 (psychedelics) opposition in 2024 drew from some medical and public-health voices; specific 2026 named opponents are unconfirmed.

Ballot initiatives

Massachusetts allows citizen-initiated ballot measures via an indirect initiative process (signatures, then legislative review window, then a second signature round to reach the ballot). The 2024 psychedelics measure (Question 4) failed, and a substantially similar measure was barred from refiling for two years. For the 2026 cycle, the Secretary of the Commonwealth certified nine questions for the November ballot on July 17, 2026, including an initiative to repeal retail recreational cannabis sales; one remaining signature challenge against the repeal question is pending before the Ballot Law Commission, with a decision expected the week of July 20 (https://www.bostonglobe.com/2026/07/17/metro/massachusetts-ballot-questions-certified-galvin/). Other certified questions reported include voter ID and same-day voter registration measures. Relevant 2026 calendar date: May 5, 2026 is listed as the last day for the Legislature to enact initiative petitions for changes in laws.

Equity and expungement

Massachusetts is a national leader in cannabis social equity. The framework includes a Social Equity Program (free statewide technical assistance and training), Economic Empowerment priority status, and a Social Equity Trust Fund created by the 2022 law update to channel capital to communities disproportionately harmed by prohibition. The December 2025 social consumption regulations reserve the first on-site consumption permits for social equity and economic empowerment applicants. H.5350 (2026) continues an equity emphasis.

Expungement and record relief: The 2022 update expedited expungement for now-decriminalized prior offenses. Governor Healey pardoned misdemeanor marijuana possession convictions predating March 13, 2024. Additional 2025-2026 bills (including a proposed state-initiated, more automatic expungement process) have been filed; specifics and bill numbers unconfirmed. Who benefits: people with low-level cannabis records and equity-designated entrepreneurs; gaps remain for felony-level or non-cannabis drug records and for capital access despite the trust fund.

Market and barriers

Tax: 10.75% state excise + 6.25% state sales tax + up to 3% optional local tax; maximum about 20% on adult use. Medical cannabis untaxed.
Market size: about $1.65 billion in adult-use sales in calendar 2025 (Commission).
License caps: single-entity cap raised from 3 to 6 licenses under H.5350; overall retail license caps lifted.
Vertical integration: no longer required for medical operators (repealed 2026).
Residency: Massachusetts does not impose a hard in-state residency ownership requirement (open to MSOs), which aids consolidation; equity and empowerment programs partly counterbalance.
License fees and capital requirements: specific 2026 application/license fee schedules are set by the Cannabis Control Commission; exact current dollar figures unconfirmed in sources reviewed (see CCC Taxes and Fees page in Sources).
Approximate number of licensees: not pinned to a single 2026 figure in sources reviewed; unconfirmed (consult the CCC licensee data portal).

Enclosure read

Cannabis: Massachusetts sits in the middle of the enclosure spectrum and is currently loosening in ways that cut both directions. Raising the single-entity license cap from 3 to 6, lifting retail caps, ending medical vertical-integration mandates, and welcoming MSOs all favor consolidation and well-capitalized operators. At the same time, the nation-leading social equity apparatus (trust fund, empowerment priority, equity-first social consumption permits) and the absence of broad decriminalization for other drugs are deliberate counterweights that keep a lane open for smaller and equity operators. Home grow (6/12 plants) keeps a genuine personal-use commons.

Hemp: This is the most heavily fenced segment. DPH/ABCC prohibitions on hemp THC and CBD food and beverages, combined with the looming federal November 2026 deadline, have collapsed the licensed hemp base by roughly 86% since 2019 and effectively fence out small hemp/beverage entrepreneurs in favor of the state-licensed cannabis channel.

Psychedelics: Fully fenced by prohibition after the 2024 ballot loss; the only openings are slow, clinically gated pilot bills that, if enacted, would route access through licensed medical settings rather than a personal-use or small-grower commons.

Justification for 3/5: Adult-use cannabis is open and even loosening on possession and delivery, with strong equity guardrails, which pulls the score down. But the loosened license caps favoring consolidation, the near-total enclosure of hemp, and prohibition of psychedelics and other drugs pull it back up. Net: moderately fenced, 3/5.

What to watch next

Cannabis Control Commission restructure: Governor must appoint 3 commissioners within ~30 days of the April 19, 2026 signing; implementation rulemaking under H.5350 ongoing through 2026.
Social consumption: regulations anticipated effective January 2, 2026; watch first equity-reserved permit issuance.
Intoxicating hemp: CCC study and recommendations mandated by H.5350; federal hemp definition change compliance deadline around November 12, 2026.
Psychedelics: fate of S.1400, H.2203, H.4200, H.4050 in the 2025-2026 session; H.4050 reporting date was extended to February 20, 2026.
Harm reduction: whether overdose prevention center authorization revives after being stripped in 2025; fentanyl test strip bill S.1057 progress.
Legislative calendar: July 31, 2026 is the last day for formal sessions in the second annual session of the 194th General Court; May 5, 2026 noted as last day to enact initiative petitions for law changes. Bills not enacted by July 31, 2026 generally must be refiled in the next (195th) session beginning January 2027.

Regulators

Cannabis Control Commission (masscannabiscontrol.com): licensing and regulation of adult-use and medical cannabis; restructured to 3 governor-appointed commissioners under H.5350; tasked with studying intoxicating hemp.
Massachusetts Department of Agricultural Resources (MDAR), Industrial Hemp Program: licenses hemp cultivators and processors under M.G.L. c.128 ss.116-123 and 330 CMR 32.00.
Massachusetts Department of Public Health (DPH): hemp-derived CBD/THC food and beverage prohibitions; Bureau of Substance Addiction Services for harm reduction, naloxone standing order, fentanyl test strip distribution; would administer any psychedelic therapy pilot.
Alcoholic Beverages Control Commission (ABCC): bans THC/CBD in alcoholic and certain other beverages on licensed premises.
Office of the Governor and the Legislature (194th General Court) for statutory policy.

Federal exposure (2026)

Massachusetts is a mature, fully legal adult-use market, so the federal levers below mostly determine which in-state actors gain or lose, not whether the market exists.

Rescheduling and 280E: Cannabis stays Schedule I by default. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III, ending IRS Section 280E for that medical category alone; recreational cannabis stays Schedule I and still cannot deduct ordinary business expenses. For Massachusetts this is mostly an asymmetric break, because the bulk of the roughly $1.65 billion 2025 market is adult-use, which gets no 280E relief. The state's own 2026 modernization law (H.5350) repealed the medical vertical-integration requirement, so a medical-only operator can now specialize in cultivation, manufacturing, or retail, and the federal Schedule III move stacks the 280E tax benefit onto exactly that narrowed medical lane. The broader DEA rescheduling hearing opened June 29, 2026 and may slip to 2027; Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not cover state recreational businesses, so Massachusetts adult-use operators remain locked inside state borders and outside normal federal tax treatment.

Hemp (the November 12, 2026 cliff): The FY2026 agriculture appropriations rider (Sec. 781, Rep. Andy Harris R-MD) narrowed the federal hemp definition to a total-THC standard of about 0.4 mg THC per container, which recriminalizes roughly 90 to 95 percent of intoxicating hemp products effective November 12, 2026. The H.R.7010 delay was not enacted, and the 2026 Farm Bill (H.R.7567) keeps the ban. Practical effect in Massachusetts: small. The state already bans hemp-derived THC and CBD in food and beverages by DPH/ABCC guidance, and the licensed hemp base has already collapsed by roughly 86 percent since 2019 to about 17 companies. The federal cliff mainly hardens an existing in-state prohibition and forecloses the path by which the Cannabis Control Commission's mandated intoxicating-hemp study (under H.5350) could have produced a permissive, federally lawful hemp-cannabinoid lane; any future state framework must now fit inside the tighter federal total-THC ceiling. Exact state rules remain unconfirmed pending that study.

Banking: SAFER Banking remains stalled in Congress, so Massachusetts cannabis operators, including adult-use businesses with no Schedule III relief, continue to face limited depository banking, higher cost of capital, and cash-handling burdens. This disadvantages thinly capitalized independents and social-equity licensees more than well-banked multistate operators, working against the state's equity guardrails.

Psychedelics: Psilocybin, MDMA, and ibogaine all remain Schedule I federally. The April 18, 2026 federal executive order plus FDA priority vouchers fast-track FDA review, but there is no approval yet. In Massachusetts, voters rejected Question 4 in 2024 (about 57-43), and therapy/pilot bills (S.1400, H.2203, H.4200, H.4050; sponsors unconfirmed, see Sources) are pending but not enacted. The likely near-term opening is therefore the federal medicalize-and-control pathway, an FDA-approved psychedelic medicine routed through licensed clinical settings, rather than a state-created personal-use or small-grower lane, which Massachusetts voters and the Legislature have so far declined to build.

Harm reduction: Massachusetts harm reduction is among the strongest in the nation (statewide naloxone standing order, legal syringe services, fentanyl test strips legalized 2024) and is exposed to federal cuts. The SAMHSA guidance of April 24, 2026 bars federal funds for fentanyl test strips, clean syringes, and sterile water, while still supporting naloxone; this puts the state's drug-checking and syringe-service funding at risk and shifts more cost onto state and local budgets. Supervised consumption (overdose prevention centers) has been repeatedly proposed and repeatedly stripped in the Legislature (associated with Rep. Marjorie Decker, Rep. John Lawn, Sen. Julian Cyr; bill numbers H.2196/S.1393 unconfirmed), and the prior July 17, 2025 HALT Fentanyl Act permanently scheduled fentanyl analogues as Schedule I, reinforcing the federal posture against any sanctioned-use site. The federal direction here adds pressure on top of the in-state political block.

Patient access and rights

This section covers what Massachusetts law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Massachusetts has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Massachusetts is not among them. The absence is the finding: a Massachusetts patient has no enforceable right to use their medicine in a hospital today.

Broader protections: Massachusetts protects a patient in one of the six areas, employment, and that protection comes from the courts rather than the cannabis statute. The medical cannabis law, Chapter 94I, contains no employment clause. But in Barbuto v. Advantage Sales and Marketing (2017), the Supreme Judicial Court held that an employee who uses medical cannabis off-site for a debilitating condition may bring a handicap-discrimination claim under the state disability law, G.L. c.151B: the employer must engage in an interactive process and, to refuse an accommodation, show undue hardship. The court stopped short of creating a right to sue under the cannabis statute itself. A review of Chapter 94I found no protection for housing, parenting, an organ transplant list, school enrollment, or general medical care. So a Massachusetts patient's real protection is a judicial one, in the employment context; the rest is the finding.

Out-of-state patients: Massachusetts does not offer medical reciprocity; adults 21 and over may purchase at adult-use retailers, but an out-of-state patient does not receive the protection described above.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Massachusetts has not enacted a Ryan's Law. The broader protections above are a creature of Massachusetts law, not federal law.

Sources: Massachusetts employment protection, Barbuto v. Advantage Sales and Marketing (Mass. 2017); medical cannabis statute, Massachusetts General Laws Chapter 94I.

Analysis: the enclosure read in depth

Who is fenced out and who consolidates: The 2026 modernization law (H.5350) reshaped an already mature market in a consolidating direction. Raising the single-entity cap from 3 to 6 licenses, lifting overall retail caps, opening statewide delivery, and the long-standing absence of a hard in-state residency requirement all favor well-capitalized multistate operators (MSOs). Ending the medical vertical-integration mandate cuts both ways: it lowers a barrier for small specialists, but combined with the federal Schedule III 280E break for medical cannabis, it most rewards operators large enough to run a tax-optimized medical arm. The actors fenced out are small independents, social-equity and economic-empowerment licensees (squeezed by stalled SAFER Banking and high capital costs), and intoxicating-hemp and hemp-beverage entrepreneurs (foreclosed by the DPH/ABCC bans and now the federal hemp cliff). The actors who consolidate are MSOs and well-banked incumbents able to absorb 280E on the adult-use side, capture the medical 280E break, hold up to 6 licenses, and operate statewide delivery.

State-plus-federal interaction: The federal posture (medicalize-and-control, enclosure favoring large incumbents) compounds rather than offsets Massachusetts's own loosening of caps. Federal Schedule III rewards the medical lane that H.5350 just made easier to specialize in; stalled banking magnifies the capital advantage that lifted caps already hand to MSOs; the November 2026 hemp cliff locks in the state's hemp prohibition; the SAMHSA cuts strain the state's strong harm-reduction system; and federal Schedule I plus the medicalize-only psychedelic pathway aligns with Massachusetts voters' 2024 rejection of a personal-use psychedelics regime. In nearly every segment, the federal layer pushes the same direction the state structure already leans: toward larger, licensed, capital-intensive incumbents.

What to watch: the Governor's three new CCC commissioners and how aggressively they enforce the higher 6-license cap; whether the CCC intoxicating-hemp study proposes anything that can survive the federal total-THC ceiling; whether SAFER Banking revives (the single biggest equalizer for small and equity operators); how the SAMHSA funding cuts hit DPH drug-checking and syringe budgets; and whether any psychedelic pilot is enacted before the federal FDA pathway defines access.

Where commons counter-moves are present: Home cultivation (6 plants per adult, 12 per household) preserves a genuine personal-use cannabis commons untouched by federal or consolidation pressure. The nation-leading equity apparatus (Social Equity Program, Economic Empowerment priority, Social Equity Trust Fund, and equity-first social consumption permits) is a deliberate counterweight, though stalled banking blunts it. Expungement and the Healey pardons reopen civic standing for people with old cannabis records. These are real but partial offsets against an otherwise consolidating, federally reinforced structure.

Justification for the 3/5 score: Adult-use cannabis is fully legal, loosening on possession and delivery, with strong equity guardrails and a real home-grow commons, which holds the score below the high end. But the federal layer now sharpens the enclosure: lifted and raised license caps plus MSO access favor consolidation, the medical-only Schedule III break and stalled banking advantage large incumbents, intoxicating hemp is near-totally fenced and now hit by the federal cliff, psychedelics are prohibited with only a clinically gated federal pathway emerging, and harm reduction faces federal funding withdrawal. The counter-moves are genuine but do not reverse the direction of travel. Net: moderately fenced and tilting toward consolidation, 3/5.

Active legislation (2026)

This list is not exhaustive. For the full long tail, see the Massachusetts Legislature site (malegislature.gov) and LegiScan (links in Sources).

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

S.2749 Senate cannabis reform companion (Passed Senate; folded into H.5350)
(various) Medical cannabis expansion (add PTSD, opioid use disorder); employment protections for consumers (Committee-approved (reported))

Bill	Title/Topic	Chamber	Status	Sponsor(s)
H.5350	An Act Modernizing the Commonwealth's Cannabis Laws (conference compromise of H.4206 / S.2749)	Both (conference)	Signed into law April 19, 2026	Conference committee; House chair Rep. Daniel Donahue (Worcester). Other conferees unconfirmed
H.4206	House cannabis reform (2 oz limit, CCC restructure, equity)	House	Passed House 153-0 (June 2025); folded into H.5350	Reported via Joint Committee on Cannabis Policy; lead sponsor unconfirmed
S.2749	Senate cannabis reform companion	Senate	Passed Senate; folded into H.5350	Unconfirmed
S.1400	Psychedelic-assisted therapy pilot program	Senate	Advanced from Joint Committee on Public Health (unanimous, Sept 2025); not enacted	Unconfirmed
H.2203	Broad psilocybin access program	House	Pending/committee	Unconfirmed
H.4200	Narrower psychedelic therapy pilot (incl. MDMA, ibogaine)	House	Pending/committee	Unconfirmed
H.4050	Adult-use psilocybin: cultivation, support services, taxation	House	Reporting date extended to Feb 20, 2026; pending	Unconfirmed
S.1057	Fentanyl test strip / drug-checking protections expansion	Senate	Advanced in Senate (Sept 2025)	Sen. Cindy Creem (reported)
H.2196 / S.1393	Overdose prevention centers authorization	House / Senate	Pending; OPC language stripped from a 2025 vehicle	Rep. Marjorie Decker, Rep. John Lawn, Sen. Julian Cyr (reported; bill numbers unconfirmed)
(various)	Medical cannabis expansion (add PTSD, opioid use disorder); employment protections for consumers	Joint Committee on Cannabis Policy	Committee-approved (reported)	Unconfirmed

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →